Idexx Laboratories Inc. (NASDAQ:IDXX) Director Thomas Craig sold 8,500 shares of Idexx Laboratories stock in a transaction on Wednesday, November 23rd. The stock was sold at an average price of $120.06, for a total transaction of $1,020,510.00. Following the completion of the transaction, the director now owns 32,783 shares in the company, valued at approximately $3,935,926.98. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of Idexx Laboratories Inc. (NASDAQ:IDXX) traded down 0.66% during mid-day trading on Monday, hitting $119.48. 450,119 shares of the stock traded hands. The firm has a market capitalization of $10.71 billion, a P/E ratio of 50.89 and a beta of 0.48. Idexx Laboratories Inc. has a one year low of $63.48 and a one year high of $120.80. The company’s 50 day moving average is $111.46 and its 200 day moving average is $103.18.
Idexx Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, November 1st. The company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. The business earned $448.30 million during the quarter, compared to the consensus estimate of $448.60 million. Idexx Laboratories had a net margin of 12.36% and a negative return on equity of 788.91%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.48 earnings per share. On average, equities analysts expect that Idexx Laboratories Inc. will post $2.38 EPS for the current fiscal year.
Several research analysts recently commented on the stock. Bank of America Corp. reiterated a “neutral” rating on shares of Idexx Laboratories in a report on Thursday, September 29th. Zacks Investment Research downgraded shares of Idexx Laboratories from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 4th. Stifel Nicolaus lifted their target price on shares of Idexx Laboratories from $120.00 to $125.00 and gave the stock a “buy” rating in a report on Tuesday, August 16th. Canaccord Genuity reiterated a “buy” rating and issued a $120.00 target price on shares of Idexx Laboratories in a report on Monday, August 22nd. Finally, Northcoast Research upgraded shares of Idexx Laboratories from a “sell” rating to a “neutral” rating in a report on Wednesday, August 3rd. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $105.20.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IDXX. Williams Jones & Associates LLC acquired a new position in Idexx Laboratories during the second quarter worth $61,058,000. Fundsmith LLP boosted its stake in shares of Idexx Laboratories by 6.1% in the second quarter. Fundsmith LLP now owns 4,469,336 shares of the company’s stock worth $415,023,000 after buying an additional 258,657 shares in the last quarter. Columbus Circle Investors boosted its stake in shares of Idexx Laboratories by 7.0% in the second quarter. Columbus Circle Investors now owns 816,808 shares of the company’s stock worth $75,849,000 after buying an additional 53,560 shares in the last quarter. Smith Asset Management Group LP purchased a new stake in shares of Idexx Laboratories during the second quarter worth approximately $12,467,000. Finally, Welch & Forbes LLC boosted its stake in shares of Idexx Laboratories by 0.6% in the second quarter. Welch & Forbes LLC now owns 198,190 shares of the company’s stock worth $18,404,000 after buying an additional 1,169 shares in the last quarter. 90.84% of the stock is owned by institutional investors and hedge funds.
Idexx Laboratories Company Profile